Our strategic approach is about advancing science to benefit patients most in need of new therapies. As a private company led ...

The adaptive, biomarker-directed trial allows researchers to enrich for best responders and open new sub-studies for non-responders based on emerging data.

Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as the most common initiating event for secondary glioblastoma, a brain tumor type arising with high frequency in the frontal ...

Introduction: Brain stem gliomas harboring IDH mutations can be sensitive to temozolomide (TMZ) treatment, unlike their H3K27-altered counterparts, so distinguishing the two is essential.Here, we ...

Here, the authors demonstrate that somatic mutations in antigen-presenting genes, including HLA class I/II and associated pathway genes, might influence the immune evasion capabilities of gliomas, ...